Candriam S.C.A. Purchases 49,409 Shares of Danaher Corporation $DHR

Candriam S.C.A. boosted its position in shares of Danaher Corporation (NYSE:DHR) by 12.3% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 451,933 shares of the conglomerate’s stock after purchasing an additional 49,409 shares during the period. Candriam S.C.A.’s holdings in Danaher were worth $89,279,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Nuveen LLC acquired a new position in shares of Danaher in the 1st quarter worth approximately $833,941,000. Generation Investment Management LLP raised its position in Danaher by 56.2% in the 2nd quarter. Generation Investment Management LLP now owns 4,965,646 shares of the conglomerate’s stock valued at $980,914,000 after purchasing an additional 1,787,522 shares during the last quarter. Invesco Ltd. boosted its stake in Danaher by 44.5% in the first quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate’s stock worth $965,259,000 after purchasing an additional 1,450,703 shares in the last quarter. Baird Financial Group Inc. grew its holdings in shares of Danaher by 290.6% during the first quarter. Baird Financial Group Inc. now owns 1,441,706 shares of the conglomerate’s stock worth $295,550,000 after purchasing an additional 1,072,617 shares during the last quarter. Finally, Parnassus Investments LLC increased its stake in shares of Danaher by 23.3% in the first quarter. Parnassus Investments LLC now owns 3,828,024 shares of the conglomerate’s stock valued at $784,745,000 after buying an additional 722,636 shares in the last quarter. 79.05% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, SVP Georgeann Couchara sold 5,174 shares of the business’s stock in a transaction on Monday, November 10th. The shares were sold at an average price of $210.42, for a total value of $1,088,713.08. Following the completion of the transaction, the senior vice president owned 2,625 shares of the company’s stock, valued at $552,352.50. The trade was a 66.34% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Teri List sold 2,778 shares of the company’s stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the sale, the director owned 20,751 shares of the company’s stock, valued at approximately $4,379,706.06. This represents a 11.81% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 11.20% of the company’s stock.

Danaher Stock Performance

Shares of Danaher stock opened at $219.60 on Thursday. The firm has a fifty day moving average of $204.76 and a two-hundred day moving average of $200.77. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.10 and a current ratio of 1.52. The stock has a market capitalization of $155.11 billion, a price-to-earnings ratio of 45.28, a PEG ratio of 3.28 and a beta of 0.81. Danaher Corporation has a 52 week low of $171.00 and a 52 week high of $258.23.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, October 21st. The conglomerate reported $1.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.72 by $0.17. The business had revenue of $6.05 billion for the quarter, compared to analyst estimates of $6 billion. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The firm’s revenue was up 4.4% on a year-over-year basis. During the same period last year, the company earned $1.71 EPS. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, equities research analysts predict that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, October 31st. Stockholders of record on Friday, September 26th were paid a $0.32 dividend. The ex-dividend date of this dividend was Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. Danaher’s dividend payout ratio is 26.39%.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the stock. Weiss Ratings reissued a “hold (c-)” rating on shares of Danaher in a report on Wednesday, October 8th. Redburn Partners set a $220.00 target price on shares of Danaher in a research report on Wednesday, October 8th. JPMorgan Chase & Co. raised their price target on shares of Danaher from $260.00 to $270.00 and gave the company an “overweight” rating in a report on Wednesday, October 22nd. Rothschild & Co Redburn restated a “neutral” rating and issued a $220.00 price objective (down previously from $245.00) on shares of Danaher in a research report on Wednesday, October 8th. Finally, Wall Street Zen lowered Danaher from a “buy” rating to a “hold” rating in a research report on Monday. Eighteen investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat.com, Danaher presently has an average rating of “Moderate Buy” and an average price target of $243.39.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.